Press release
Major Industry Participants Consolidating Their Presence in the Adalimumab, Infliximab, and Etanercept Biosimilars Market
Adalimumab, Infliximab and Etanercept Biosimilars Market
Forecast of Market Size for Adalimumab, Infliximab, and Etanercept Biosimilars by 2030
The market for biosimilars of adalimumab, infliximab, and etanercept is anticipated to grow rapidly, reaching a valuation of $8.05 billion by 2030. This growth represents a compound annual growth rate (CAGR) of 10.1% over the forecast period. Several factors are contributing to this upward trajectory, such as breakthroughs in precision medicine, the expansion of biosimilar development pipelines, increased healthcare spending, growing acceptance of digital health technologies, and an aging global population.
Download a free sample of the adalimumab, infliximab and etanercept biosimilars market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3473&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
Key Drivers Supporting Growth in the Biosimilars Market
Advancements in precision medicine are playing a crucial role in expanding the reach and effectiveness of biosimilars, making treatments more tailored and efficient. Moreover, the development pipelines for biosimilars are broadening, allowing more products to enter the market and improve patient access.
Rising healthcare expenditures worldwide and the increased use of digital health solutions are also important contributors to market growth. Additionally, the demographic trend of an aging population is driving higher demand for treatments targeting chronic inflammatory diseases, which these biosimilars address.
View the full adalimumab, infliximab and etanercept biosimilars market report:
https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilar-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
Leading Companies Making an Impact in Adalimumab, Infliximab, and Etanercept Biosimilars
A number of prominent companies dominate the market landscape, including Biogen, Novartis (Sandoz), Pfizer, Amgen, Celltrion, Samsung Bioepis (Samsung Biologics), Hetero Drugs Limited, Fresenius Kabi AG, Boehringer Ingelheim, Biocon, Zydus Lifesciences Limited, Reliance Life Sciences, Torrent Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Cipla Limited, Zhejiang Hisun Pharmaceutical Co. Ltd, Bio-Thera Solutions Ltd, Innovent Biologics (Suzhou) Co. Ltd, Janssen Biologics BV, Shanghai CP Guojian Pharmaceutical Co. Ltd, Sansheng Guojian, Shanghai Junshi Biosciences Co. Ltd, Mabwell Bioscience Co. Ltd, LG Chem, Nippon Kayaku, Mochida Pharmaceutical Co. Ltd, mAbxience, Allergan, Microgen, Geropharm, Valenta, NovaMedica Veropharm, and Biocad.
Notable Acquisition Highlighting Market Expansion
In November 2024, Celltrion, a South Korean therapeutics firm, acquired iQone Healthcare for an undisclosed sum. This strategic move is intended to enhance Celltrion's direct commercialization efforts of biosimilars within Europe. The acquisition aims to strengthen Celltrion's market presence, expand distribution channels, and improve patient access to innovative therapies. iQone Healthcare, based in Switzerland, specializes in manufacturing and commercializing biosimilars and treatments for rare diseases.
Technological Trends Influencing the Biosimilars Industry
Companies in the adalimumab, infliximab, and etanercept biosimilars space are increasingly focusing on innovations like high-concentration, citrate-free biosimilars. These formulations offer the same monoclonal antibody structure as traditional biosimilars but improve patient experience by reducing injection discomfort. This can lead to better adherence and higher rates of switching to biosimilars.
An example of this trend occurred in June 2023 when Celltrion USA launched Yuflyma (adalimumab-aaty), a citrate-free, high-concentration (100 mg/mL) biosimilar alternative to Humira (adalimumab). Yuflyma maintains the therapeutic efficacy of adalimumab while offering enhanced tolerability, making it an attractive option in the treatment of chronic inflammatory conditions and supporting wider adoption in immunology.
Segments Defining the Adalimumab, Infliximab, and Etanercept Biosimilars Market
The report categorizes the biosimilars market into several key segments:
By Product Type:
- Adalimumab Biosimilars
- Infliximab Biosimilars
- Cipleumab
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Application Area:
- Crohn's Disease
- Psoriatic Arthritis
- Rheumatoid Arthritis
- Ulcerative Colitis
- Ankylosing Spondylitis
- Plaque Psoriasis
- Other Applications
Further sub-segments for Adalimumab Biosimilars include Amjevita (Amgen), Hyrimoz (Sandoz), Cyltezo (Boehringer Ingelheim), and others. Infliximab Biosimilars cover products such as Inflectra (Pfizer), Remsima (Celltrion), Ixifi (Pfizer), among others. The Cipleumab category includes biosimilars currently on the market as well as those still under development.
Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Major Industry Participants Consolidating Their Presence in the Adalimumab, Infliximab, and Etanercept Biosimilars Market here
News-ID: 4494798 • Views: …
More Releases from The Business Research Company
Leading Companies Fueling Innovation and Growth in the Alcohol Excipients Market
The alcohol excipients market is on track for significant expansion over the coming years, driven by various factors within the pharmaceutical and personal care sectors. As the demand for specialized and efficient drug formulations increases, this market is poised for notable growth and innovation. Let's delve into the current outlook, major players, and detailed segments shaping this industry.
Projected Growth and Market Size of the Alcohol Excipients Market by 2030 …
An Overview of Segmentation, Market Dynamics, and Competitive Landscape in the A …
The advanced therapy medicinal products sector is set to experience remarkable expansion over the coming years, driven by cutting-edge technological developments and increasing demand for personalized treatment options. This dynamic market is evolving rapidly as innovations in gene editing, stem cell therapies, and AI integration reshape how complex diseases are treated. Let's explore the market's size, key players, emerging trends, and the segments that dominate this promising field.
Strong Growth Forecast…
Trends in Growth, Segment Analysis, and Competitive Strategies Influencing the A …
The acne drugs industry is on a steady growth path as it evolves to meet rising consumer needs and innovative treatment options. Advances in formulations and digital health are reshaping the market landscape, creating new opportunities for both established companies and emerging players. Here is a detailed overview of the acne drugs market size, key players, driving trends, and segmentation insights.
Projected Market Size of the Acne Drugs Industry by 2030…
Analysis of Key Market Segments Influencing the 2D Cell Culture Market
A growing emphasis on cellular research and drug development is propelling the 2D cell culture market toward substantial expansion. As scientific methods evolve and new technologies emerge, the demand for reliable and reproducible cell culture models is increasing. This momentum is expected to drive significant market growth over the next several years.
Forecasted Market Size and Growth Rate of the 2D Cell Culture Market
The 2D cell culture market is…
More Releases for Biosimilars
Transformative Trends Impacting the Biosimilars Market Landscape: Innovative Pro …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Biosimilars Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The dimensions of the biosimilars market have been rapidly expanding over the last couple of years. The escalation, from a worth of $18.65 billion in 2024 to an estimated value of $21.95 billion in 2025, denotes…
Evolving Market Trends In The Biosimilars Industry: Innovative Product Launched …
The Biosimilars Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Biosimilars Market Size During the Forecast Period?
The dimension of the biosimilars market has experienced substantial expansion in the last few years. The market value, which was at $18.65 billion in 2024,…
Prominent Rituximab Biosimilars Market Trend for 2025: Collaborative Innovations …
Which drivers are expected to have the greatest impact on the over the rituximab biosimilars market's growth?
The rituximab biosimilars market is anticipated to grow due to the projected increase in non-Hodgkin's lymphoma (NHL) cases. NHL is a cancer that originates in the white blood cells and lymphocytes, which are integral parts of the body's immune system. For example, the American Cancer Society, a cancer advocacy group based in the US,…
Global Oncology Biosimilars Market | Global Oncology Biosimilars Industry | Onco …
The oncology biosimilars market involves of sales of medicine and drug interrelated products for cancer treatment. Biosimilars are pharmaceuticals which are produced using cell lines and are fashionable to the manufacturer. The manufacturing of such cell line processes is a multipart and time-consuming procedure.
According to the report analysis, ‘Oncology Biosimilars Market Global Report 2020-30’ states that the worldwide oncology biosimilars market was worth USD 2990.34 million in 2019. It is…
Global Biosimilars Market | Global Biosimilars Industry | Global Biosimilars Mar …
The biosimilars market involves of sales of biosimilars and associated services that are cast-off to treat chronic sicknesses such as diabetes, arthritis, and cancer. The Biosimilars are pharmaceuticals that are produced using cell lines and offers no clinical difference as linked to biologics. The Biosimilars are made once the patent of biologics is deceased.
According to the report analysis, ‘Biosimilars Market Global Report 2020-30’ states that the worldwide biosimilars market was…
Insulin Biosimilars Market, by Biosimilar Type Rapid-acting Biosimilars, Long-ac …
Diabetes is a group of metabolic disease characterized by high blood sugar level due to inadequate secretion of insulin. Common symptoms of diabetes include increased hunger, tiredness, weight loss, and excessive thirst and urination. The prevalence of diabetes is increasing, in turn, boosting demand for insulin biosimilar. For instance, according the World Health Organization (WHO) report in 2014, globally around 422 million adults were living with diabetes and 1.5 million…
